Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications. WEXFORD, Pa., Feb. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that ...